Study points to value of HPV screening for cervical cancer: Test may be viable alternative to Pap test

Publisher： John Wiley & Sons Inc

E-ISSN： 1097-0142|120|23|3589-3590

ISSN： 0008-543x

Source： CANCER, Vol.120, Iss.23, 2014-12, pp. : 3589-3590

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Prior high‐risk HPV testing and Pap test results for 427 invasive cervical cancers in China's largest CAP‐certified laboratory

By  

CANCER CYTOPATHOLOGY, Vol. 123, Iss. 7, 2015-07 ,pp. : 428-434

John Wiley & Sons Inc

Access to resources Recommend Favorite

History of high‐risk HPV and Pap test results in a large cohort of patients with invasive cervical carcinoma: Experience from the largest women's hospital in China

By  

CANCER CYTOPATHOLOGY, Vol. 123, Iss. 7, 2015-07 ,pp. : 421-427

John Wiley & Sons Inc

Access to resources Recommend Favorite

The Pap test and Bethesda 2014

By  

CANCER CYTOPATHOLOGY, Vol. 123, Iss. 5, 2015-05 ,pp. : 271-281

John Wiley & Sons Inc

Access to resources Recommend Favorite

One HPV vaccine dose may prevent cervical cancer

By  

CANCER, Vol. 120, Iss. 6, 2014-03 ,pp. : 772-773

John Wiley & Sons Inc

Access to resources Recommend Favorite

Cervical cancer screening in low‐resource settings: A cost‐effectiveness framework for valuing tradeoffs between test performance and program coverage

By  

INTERNATIONAL JOURNAL OF CANCER, Vol. 137, Iss. 9, 2015-11 ,pp. : 2208-2219

John Wiley & Sons Inc

Access to resources Recommend Favorite